NEW YORK (GenomeWeb News) – CombiMatrix today said that Pathology, Inc. will market and distribute its chromosomal microarray tests for "products of conception" testing in designated areas in the US.

Products of conception testing enables physicians to better determine if there is a genetic cause behind a miscarriage or multiple events, said Irvine, Calif.-based CombiMatrix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.